PuriCore Plc Grant of Options (5192P)
November 18 2016 - 1:01AM
UK Regulatory
TIDMPURI
RNS Number : 5192P
PuriCore Plc
18 November 2016
PuriCore plc
("PuriCore" or the "Company")
Grant of Options
18 November 2016 - PuriCore plc (AIM: PURI), announces the grant
of up to 1,425,000 share options to its directors to subscribe for
ordinary shares of 10p each (the "Shares") in the capital of the
Company (the "Options"). All Options were granted on 17 November
2016 (the "Grant Date"), have an exercise price of 29.50 pence each
and a five year term.
Grants were made to Executive Directors, under the PuriCore
Executive Omnibus Incentive Plan 2016 (the "Plan"), as noted below.
The Options vest one-third per year on each of the first three
anniversaries of the Grant Date on the basis of attainment of
certain key performance measures relating to clinical development
and other strategic targets, which will be evaluated on the
relevant anniversaries.
Name Title Grant Amount
Alex Martin Chief Executive Officer Up to 500,000 Shares
Marella Thorell Chief Financial & Operating Up to 500,000 Shares
Officer
Grants were made to Non-Executive Directors, under individual
agreements which are subject to the provisions of the Plan, as
noted below. The Options vest one-third per year on each of the
first three anniversaries of the Grant Date.
Name Role Grant Amount
Charles Spicer Non-Executive Chairman Up to 100,000
Shares
William Birkett Senior Independent Non-Executive Up to 65,000
Director Shares
Balkrishan(Simba) Non-Executive Director Up to 65,000
Gill Shares
Matthew Hammond Non-Executive Director Up to 65,000
Shares
Daniel Hegglin Non-Executive Director Up to 65,000
Shares
Peter Larkin Non-Executive Director Up to 65,000
Shares
Following the above grants there is a total of approximately 4.4
million options over ordinary shares outstanding which represents
approximately 8.75% of the current issued share capital of the
Company.
Enquiries:
PuriCore plc +44 (0) 20 3727 1000
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial
Officer and Chief Operating Officer
FTI Consulting +44 (0) 20 3727 1000
Simon Conway / Mo Noonan
N+1 Singer (Nominated Adviser
& Broker) +44 (0) 20 7496 3000
Aubrey Powell / Jen Boorer
About PuriCore
PuriCore is an emerging specialty biopharmaceutical company
focused on developing novel immunomodulatory therapies to protect
and improve the lives of adults and children. The Company has
initiated a drug development program, based on its proprietary
hypochlorous acid technology at high concentrations. The Company
believes their formulations have novel immunomodulatory activity
with potential application for the treatment of diseases in a
number of therapeutic areas including Dermatology and
Ophthalmology.
1 Details of the person discharging managerial
responsibilities/person closely associated
with them
---- -------------------------------------------------------------------
a) Name 1. Alex Martin
2. Marella Thorell
3. Charles Spicer
4. William Birkett
5. Balkrishan (Simba)
Gill
6. Matthew Hammond
7. Daniel Hegglin
8. Peter Larkin
---- --------------------------------- --------------------------------
2 Reason for notification
---- -------------------------------------------------------------------
a) Position/status 1. Chief Executive
Officer
2. Chief Financial
& Operating Officer
3. Non-Executive
Chairman
4. Senior Independent
Non-Executive Director
5. Non-Executive
Director
6. Non-Executive
Director
7. Non-Executive
Director
8. Non-Executive
Director
---- --------------------------------- --------------------------------
b) Initial notification/Amendment Initial Notification
---- --------------------------------- --------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
---- -------------------------------------------------------------------
a) Name PuriCore PLC
---- --------------------------------- --------------------------------
b) LEI n/a
---- --------------------------------- --------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date;
and (iv) each place where transactions have
been conducted
---- -------------------------------------------------------------------
a) Description of the financial Ordinary shares
instrument, type of instrument in Puricore PLC
Identification code ISIN: GB00B3XBCR18
---- --------------------------------- --------------------------------
b) Nature of transaction Grant of options
over 1,425,000 shares
under the PuriCore
Executive Omnibus
Incentive Plan 2016
and individual agreements
---- --------------------------------- --------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---- --------------------------------- ---------------- --------------
1. 29.50
pence
2. 29.50
pence
3. 29.50
pence
4. 29.50
pence
5. 29.50 500,000
pence 500,000
6. 29.50 100,000
pence 65,000
7. 29.50 65,000
pence 65,000
8. 29.50 65,000
pence 65,000
------------------------------------------------------- --------------
d) Aggregated information n/a (Single transaction)
* Aggregated volume
* Price
---- --------------------------------- --------------------------------
e) Date of the transaction 17 November 2016
---- --------------------------------- --------------------------------
f) Place of the transaction Outside a trading
venue
---- --------------------------------- --------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGGGMUGUPQPGM
(END) Dow Jones Newswires
November 18, 2016 02:01 ET (07:01 GMT)
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Apr 2024 to May 2024
Realm Thera. (LSE:RLM)
Historical Stock Chart
From May 2023 to May 2024